300665-25-2

Basic information

• Product Name: [2-(morpholin-4-yl)-5-nitrophenyl]methanol
• Synonyms: [2-(morpholin-4-yl)-5-nitrophenyl]methanol
• CAS NO: 300665-25-2
• Molecular Formula: C₁₁H₁₄N₂O₄
• Molecular Weight: 238.25
• Mol File: 300665-25-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [2-(morpholin-4-yl)-5-nitrophenyl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(morpholin-4-yl)-5-nitrophenyl]methanol(300665-25-2)
• EPA Substance Registry System: [2-(morpholin-4-yl)-5-nitrophenyl]methanol(300665-25-2)

Safety Data

• Hazardous Substances Data: 300665-25-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
[2-(morpholin-4-yl)-5-nitrophenyl]methanol is used as a building block for the synthesis of new molecules with potential therapeutic uses. Its unique structure, which includes a morpholine ring, a nitro group, and a phenyl group, contributes to its versatility in creating molecules with diverse applications in the pharmaceutical industry.
Used in Organic Chemistry Research:
[2-(morpholin-4-yl)-5-nitrophenyl]methanol is used as a valuable tool in organic chemistry research due to its ability to undergo further modification and functionalization through its hydroxyl group. This characteristic makes it an essential component in the development of novel chemical compounds and the advancement of organic chemistry.
Used in Chemical Synthesis:
[2-(morpholin-4-yl)-5-nitrophenyl]methanol is used as an intermediate in the synthesis of various organic compounds. Its unique structure and properties make it a preferred choice for creating a wide range of molecules with different applications across various industries.

Upstream product

• 30742-62-2 2-(N-morpholinyl)-5-nitrobenzaldehyde 
• 110-91-8 morpholine 
• 63878-73-9 (2-fluoro-5-nitrophenyl)methanol 
• 27996-87-8 2-fluoro-5-nitrobenzaldehye 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 

Downstream Products

• 759456-60-5 (5-amino-2-morpholinophenyl)methanol 
• 1187660-13-4 C₂₃H₂₄N₄O₄ 
• 1039916-75-0 C₁₁H₁₃ClN₂O₃ 
• 1071217-84-9 7-chloro-N-[4-morpholino-3-(pyrrolidinomethyl)phenyl]quinolin-4-amine 
• 1312291-25-0 N-{3-[(tert-butylamino)methyl]-4-morpholinophenyl}-7-chloroquinolin-4-amine 
• 1312291-27-2 7-chloro-N-[4-morpholino-3-(morpholinomethyl)phenyl]quinolin-4-amine 
• 1312291-24-9 7-chloro-N-{3-[(4-methylpiperazino)methyl]-4-morpholinophenyl}quinolin-4-amine 
• 1312291-23-8 {5-[(7-chloroquinolin-4-yl)amino]-2-morpholinophenyl}methanol hydrochloride 
• 1312291-26-1 7-chloro-N-[3-({[2-(dimethylamino)ethyl](methyl)amino}methyl)-4-(morpholin-4-yl)phenyl]quinolin-4-amine 
• 1056636-17-9 3-allyloxymethyl-4-morpholin-4-yl-phenylamine 
• 1312603-53-4 (3-allyloxymethyl-4-morpholin-4-yl-phenyl)-[4-(3-allyloxymethylphenyl)-pyrimidin-2-yl]-amine 
• 1312603-38-5 4-(2-allyloxymethyl-4-nitrophenyl)morpholine 
• 957346-19-9 3-(tert-butyl-dimethyl-silanyloxymethyl)-4-morpholin-4-yl-phenylamine 
• 959755-64-7 [5-(5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamino)-2-morpholin-4-yl-phenyl]-methanol 

Relevant articles and documents

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27) ,16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2 V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2 WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.

7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: Easy access to analogs

Amodiaquine is one of the most active antimalarial 4-aminoquinoline. Previously we have described new analogs of amodiaquine and amopyroquine, in which the hydroxyl group was replaced by various amino groups and identified highly potent compounds. Here we

4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS

The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following (formula I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.